Two cell‑therapy programs reported meaningful clinical progress this week. A phase 1 trial of allogeneic iPSC‑derived invariant natural killer T (iNKT) cells demonstrated early safety signals and tolerability in recurrent head and neck cancer patients, advancing interest in off‑the‑shelf immune cell platforms. Separately, Vigencell reported that VT‑EBV‑N, an antigen‑specific killer T‑cell therapy for natural killer T‑cell lymphoma (NKTCL), met its Phase II endpoint; the company plans to pursue conditional approval in South Korea. Both updates highlight divergent cell‑therapy approaches—universal iPSC‑derived products versus antigen‑specific autologous or allogeneic T cells—and reinforce regulatory momentum for expedited pathways in high‑need oncology indications.